Comerica Bank
OTLK icon

Comerica Bank’s Outlook Therapeutics OTLK Stock Holding History

Comerica Bank’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-488
Closed -$2.61K – 3724
2024
Q3 		$2.61K Hold
488
– – ﹤0.01% 3456
2024
Q2 		$3.6K Buy
+488
New +$3.92K ﹤0.01% 3364

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Comerica Bank's OTLK Position: Q4 2024 in Review

Comerica Bank sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 488 shares — an estimated $2.61K sold.

Comerica Bank first reported a position in OTLK in Q2 2024 and held it in 2 quarters. The position peaked at $3.6K in Q2 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Comerica Bank reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Comerica Bank sold 488 Outlook Therapeutics shares in Q4 2024, an estimated $2.61K.
  • Comerica Bank first reported a position in Outlook Therapeutics in Q2 2024 and held it in 2 quarters.
  • Comerica Bank's Outlook Therapeutics position peaked at $3.6K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Comerica Bank's 13F filing for Q4 2024, filed 14 Feb 2025.